Effects of polyunsaturated fatty acid consumption in diabetic nephropathy

Nature Reviews Nephrology

Volumn 7, Issue 2, 2011, Pages 110-121

  Shapiro, Haim ^a   Theilla, Miryam ^a   Attal Singer, Joelle ^a   Singer, Pierre ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID; STEARIDONIC ACID;

ALBUMINURIA; CEREBROVASCULAR DISEASE; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; FOOD INTAKE; GLOMERULAR DYSFUNCTION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; MEDICAL RESEARCH; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RESPIRATORY DISTRESS SYNDROME; REVIEW; RHEUMATOID ARTHRITIS; SUPPLEMENTATION;

ALBUMINURIA; DIABETIC NEPHROPATHIES; FATTY ACIDS, UNSATURATED; HUMANS; KIDNEY;

EID: 79551520295     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.156     Document Type: Review

References (76)

1. th edn Ch. 338 (eds Fauci, A. S. et al.) 2275-2304 (McGraw-Hill Professional, New York, 2008).
2. Molitch, M. E. et al. Nephropathy in diabetes. Diabetes Care 27 (Suppl. 1), S79-S83 (2004).
3. th edn Ch. 15 (eds Murray, R. K., Granner, D. K. & Rodwell V. W.) 121-131 (McGraw-Hill Medical, New York, 2006).
4. Kris-Etherton, P.M., Harris, W. S. & Appel, L. J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 2747-2757 (2002).
5. Harris, W. S. et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119, 902-907 (2009).
6. Calder, P C. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 77, 327-335 (2007).
7. Donadio, J. V. & Grande, J. P. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin. Nephrol. 24, 225-243 (2004).
8. Friedman, A. & Moe, S. Review of the effects of omega-3 supplementation in dialysis patients. Clin. J. Am. Soc. Nephrol. 1, 182-192 (2006).
9. Higdon, J. in An Evidence-Based Approach to Dietary Phytochemicals 78-99 (Thieme Medical Publishers, New York, 2006).
10. Simopoulos, A. P. Evolutionary aspects of the dietary omega-6: omega-3 fatty acid ratio: medical implications. World Rev. Nutr. Diet. 100, 1-21 (2009).
11. Hao, C. M. & Breyer, M. D. Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 71, 1105-1115 (2007).
12. Camara, N. O., Martins, J. O., Landgraf, R. G. & Jancar, S. Emerging roles for eicosanoids in renal diseases. Curr. Opin. Nephrol. Hypertens. 18, 21-27 (2009).
13. Zhao, X. & Imig, J. D. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr. Drug Metab. 4, 73-84 (2003).
14. Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 50 (Suppl.), S52-S56 (2009).
15. Lauterbach, B. et al. Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39, 609-613 (2002).
16. Hercule, H. C. et al. The vasodilator 17, 18-epoxyeicosatetraenoic acid targets the pore-forming BK alpha channel subunit in rodents. Exp. Physiol. 92, 1067-1076 (2007).
17. Olearczyk, J. J. et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond.) 116, 61-70 (2009).
18. Fer, M. et al. Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J. Lipid Res. 49, 2379-2389 (2008).
19. Hardwick, J. P. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem. Pharmacol. 75, 2263-2275 (2008).
20. Rodgers, K., McMahon, B., Mitchell, D., Sadlier, D. & Godson, C. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 167, 683-694 (2005).
21. Duffield, J. S. et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911 (2006).
22. Zhang, J., Sasaki, S., Amano, K. & Kesteloot, H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev. Med. 28, 520-529 (1999).
23. Hu, F B., Cho, E., Rexrode, K. M., Albert, C. M. & Manson, J. E. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107, 1852-1857 (2003).
24. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) [online], http://clinicaltrials.aov/ct2/show/NCT00069784 (2010).
25. ASCEND;A Study of Cardiovascular Events iN Diabetes [online], http://clinicaltrials.gov/ct2/show/NCT00135226 (2010).
26. Hooper, L. et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 332, 752-760 (2006).
27. Bantle, J. P. et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31 (Suppl. 1), S61-S78 (2008).
28. De Caterina, R., Madonna, R., Bertolotto, A. & Schmidt, E. B. N-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. Diabetes Care 30, 1012-1026 (2007).
29. Kris-Etherton, P. M. & Hill, A. M. N-3 fatty acids: food or supplements? J. Am. Diet. Assoc. 108, 1125-1130 (2008).
30. Brenna, J. I, Salem, N. Jr, Sinclair, A. J. & Cunnane, S. C. Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fatty Acids 80, 85-91 (2009).
31. Burdge, G. Alpha-linolenic acid metabolism in men and women: nutritional and biological implications. Curr. Opin. Clin. Nutr. Metab. Care 7, 137-144 (2004).
32. Schaeffer, L. et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum. Mol. Genet. 15, 1745-1756 (2006).
33. Zhou. Y. E., Kubow, S., Dewailly, E., Julien, P., Egeland, G. M. Decreased activity of desaturase 5 in association with obesity and insulin resistance aggravates declining long-chain n-3 fatty acid status in Cree undergoing dietary transition. Br. J. Nutr. 102, 888-894 (2009).
34. Goyens, P. L, Spilker, M. E., Zock, P. L, Katan, M. B. & Mensink, R. P. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am. J. Clin. Nutr. 84, 44-53 (2006).
35. Lane, J. T. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am. J. Physiol. Renal Physiol. 286, F442-F450 (2004).
36. Hagiwara, S. et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol. Dial. Transplant. 21, 605-615 (2006).
37. Zhang, M. et al. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA (y)/Ta mice: involvement of anti-inflammation and antioxidative stress. Metabolism 55, 1590-1598 (2006).
38. Garman, J. H., Mulroney, S., Manigrasso, M., Flynn, E. & Marie, C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am. J. Physiol. Renal Physiol. 296, F306-F316 (2009).
39. Jia, Q., Shi, Y, Bennink, M. B. & Pestka, J. J. Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice. J. Nutr. 134, 1353-1361 (2004).
40. Moon, Y. A., Hammer, R. E. & Horton, J. D. Deletion of EL0VL5 leads to fatty liver through activation of SREBP-lc in mice. J. Lipid Res. 50, 412-423 (2009).
41. Logan, J. L. Studies on the impact of dietary fat composition on proteinuria in diabetic rats. Diabetes Res. Clin. Pract. 33, 21-29 (1996).
42. Berdanier, C. D., Johnson, B., Hartle, D. K. & Crowell, W. Life span is shortened in BHE/cdb rats fed a diet containing 9% menhaden oil and 1% corn oil. J. Nutr. 122, 1309-1317 (1992).
43. Singer, P et al. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 34, 1580-1592 (2008).
44. Galli, C. & Calder, P C. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann. Nutr. Metab. 55, 123-139 (2009).
45. Chaudhary, A., Mishra, A. & Sethi, S. Oxidized omega-3 fatty acids inhibit pro-inflammatory responses in glomerular endothelial cells. Nephron Exp. Nephrol. 97, el36-el45 (2004).
46. Li, H. et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int. 67, 867-874 (2005).
47. Diaz Encarnacion, M. M. et al. Signaling pathways modulated by fish oil in salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 294, F1323-F1335 (2008).
48. An, W. S., Kim, H. J., Cho, K. H. & Vaziri, N. D. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am. J. Physiol. Renal Physiol. 297, F895-F903 (2009).
49. Theuer, J. et al. Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage. Kidney Int. 67, 248-258 (2005).
50. Ferraro, P M., Ferraccioli, G. E, Gambaro, G., Fulignati, P., Costanzi. S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol. Dial. Transplant. 24, 156-160 (2009).
51. rd, Seidler, A. J. & Whelton, P K. Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. Arch. Intern. Med. 153, 1429-1438 (1993).
52. Morris, M. C, Sacks, F. & Rosner, B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88, 523-533 (1993).
53. Geleijnse, J. M., Giltay, E. J., Grobbee, D. E., Donders, A. R. & Kok, F. J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 20, 1493-1499 (2002).
54. Hilpert, K. F et al. Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am. J. Clin. Nutr. 85, 369-376 (2007).
55. McVeigh, G. E. et al. Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36, 33-38 (1993).
56. Hartweg, J. et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD003205. doi:10.1002/14651858. CD003205.pub2 (2008).
57. Pownall, H. J. et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143, 285-297 (1999).
58. Wang, Z. et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54, 2328-2335 (2005).
59. Proctor, G. et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and 0VE26 mice with type 1 diabetes. Diabetes 55, 2502-2509 (2006).
60. Lee. C. C., Sharp, S. J., Wexler, D. J. & Adler, A. I. Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial. Diabetes Care 33, 1454-1456 (2010).
61. [No authors listed] The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes 35, 530-545 (1986).
62. Cardenas, C, Bordiu, E., Bagazgoitia, J. & Calle-Pascual, A. L. Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. Diabetes Care 27, 1454-1457 (2004).
63. Lee, C. T. et al. Cross-sectional association between fish consumption and albuminuria: the European Prospective Investigation of Cancer-Norfolk Study. Am. J. Kidney Dis. 52, 876-886 (2008).
64. Mollsten. A. V, Dahlquist, G. G., Stattin, E. L. & Rudberg, S. Higher intakes offish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Diabetes Care 24, 805-810 (2001).
65. Perassolo, M. S. et al. Fatty acid composition of serum lipid fractions in type 2 diabetic patients with microalbuminuria. Diabetes Care 26, 613-618 (2003).
66. Tilvis, R. S., Taskinen, M. R. & Miettinen. T. A. Effect of insulin treatment on fatty acids of plasma and erythrocyte membrane lipids in type 2 diabetes. Clin. Chim. Acta 171, 293-303 (1988).
67. rd et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am. J. Clin. Nutr. 89, 1937-1945 (2009).
68. Haines, A. R et al. Effects of a fish oil supplement on platelet function, haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb. Res. 43, 643-655 (1986).
69. Jensen, T, Stender, S., Goldstein, K., Hølmer, G. & Deckert, T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N. Engl. J. Med. 321, 1572-1577 (1989).
70. Hamazaki, T. Takazakura, E., Osawa, K., Urakaze, M. & Yano, S. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids 25, 541-545 (1990).
71. Shimizu, H. et al. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res. Clin. Pract. 28, 35-40 (1995).
72. Rossing, R. et al. Fish oil in diabetic nephropathy. Diabetes Care 19, 1214-1219 (1996).
73. Lungershausen, Y. K. et al. Evaluation of an omega-3 fatty acid supplement in diabetics with microalbuminuria. Ann. NY Acad. Sci. 827, 369-381 (1997).
74. Zeman, M. et al. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J. Nutr. Biochem. 17, 379-384 (2006).
75. Wong, C. Y et al. Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with type 2 diabetes mellitus. Diabet. Med. 27, 54-60 (2010).
76. De Lorenzo, A. et al. The effects of Italian Mediterranean organic diet (IMOD) on health status. Curr. Pharm. Des. 16, 814-824 (2010).